Your Partner. For science. For life.

Battling chronic ailments. Evolving science. Improving quality of life. Even helping people get a better night’s sleep. Our portfolio companies are positively impacting the world every day with their visionary people and life-changing products.

What they do.

Enzymatics is a leading producer of sample preparation reagents, diagnostic assays, kits, and software for life science research and applied science customers worldwide. The company develops and manufacture enzymes, buffers, formulations and has a complete product portfolio that complements high value industrial PCR, NGS, SynBio markets.

Status:

PBM Capital partners founded Enzymatics and were on the Board until 2015 when it sold the business to Qiagen (NASDAQ:QGEN).

Achievement of Note:

Enzymatics is widely recognized as designing and producing the world’s best molecular biology enzymes. Their enzymes are used in over 75% of all sequencing reactions globally.

How they‘re improving the quality of peoples lives:

Enzymatics has been an enabling factor in rapid decline in cost of next-gen sequencing. This reduction in cost is a catalyst for a new segment of nucleic acid-based diagnostics that will revolutionize personalized healthcare.